Formulation and Evaluation of Vaginal Suppositories Containing Lactobacillus

Authors: Sanae Kaewnopparat, Nattha Kaewnopparat

Abstract:

The objective of this study was to develop vaginal suppository containing lactobacillus. Four kinds of vaginal suppositories containing Lactobacillus paracasei HL32 were formulated: 1) a conventional suppository with Witepsol H-15 as a base, 2) a conventional suppository with mixed polyethylene glycols (PEGs) as a base, 3) a hollow-type suppository with Witepsol H-15 as a base and 4) a hollow-type suppository with mixed PEGs as a base. The release studies demonstrated that the hollow-type suppository with mixed PEGs as the base gave the highest release of L. paracasei HL32 and was microbiological stable after storage at 2- 8°C over the period of 3 months.

Keywords: Lactobacillus paracasei HL32, vaginal suppository, release study, hollow-type, viability.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1084504

References:

[1] S. Uehara, K. Monden, K. Nomoto, Y. Seno, R. Kariyam, and H. Kumon, "A pilot study evaluating the safety and effectiveness of lactobacillus vaginal suppositories in patients with recurrent urinary tract infectin," Int. J. Microbiol. Agent, vol. 285, pp. 530-534, 2006.
[2] F.M.E. Wagenlehner, and K.G. Naber, "Treatment of bacterial urinary tract infections presence and future," Eur. Urol. vol. 49, pp. 235-244, 2006.
[3] G. Reid, "Potential prevents strategies and therapies in urinary tract infection," World J. Urol., vol. 17, pp. 359-363, 1999.
[4] C.M. Slaver, "Lactobacillus: a Review," Clin. Microbiol. Newsletter, vol. 30, pp. 23-27, 2008.
[5] Report of a joint FAO/WHO Expert consultation on health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. American and Cordopa Park Hotel, Cordoba, Argentina, 1-4 October 2001. http://www.who.int/foodsafety/publications/fs_management /en/probiotics.pdf.
[6] C. Dunne, L. O-Mahony, G. Thomton, G.M. Feeney, C. Daly, G. O-Sullivan, and K. Collins, "In vitro selection criteria for probiotic bacteria of human origin correlation with in vitro findings," Am. J. Clin. Nutr., vol. 73, pp. 386-392, 2001.
[7] J. Lepargneur, and V. Rousseau, "Role protecteur de la flore de Doderlein," J. Gynecol. Obstet. Biol. Reprod., vol. 31, pp. 485-494, 2002.
[8] G. Reid, and J. Burton, "Use of lactobacillus to prevent infection by pathogenic bacteria," Microbes. Infect., vol. 4, pp. 319-324, 2002.
[9] A. Hallen, C. Jarstran, and C. Pahlson, "Treatment of bacterial vaginosis with lactobacilli," Sex Transm. Dis., vol 19, pp. 146-148, 1992.
[10] Shalev, S. Battino, E. Weiner, R. Colodner, Y. Keness, "Ingestion of yogurt containing Lactobacillus acidophilus compared with pasteurized yogurt as prophylaxis for recurrent candidial vaginitis and bacterial vaginosis," Arch. Farm. Med., vol. 5, pp. 593-596, 1996.
[11] V.V. Kale, R.V. Trivedi, and P. Sanjay, "Development and evaluation of a suppository formulation containing lactobacillus and its application in vaginal diseases," Ann. N.Y. Acad. Sci., vol. 1056, pp. 359-365, 2005.
[12] K. Pongsomboon, S. Kaewnopparat, T. Pitakpornpreecha, and T. Srichana, "Antibacterial activity of a bacteriocin from Lactobacillus paracasei HL32 against Porphyromonas gingivalis," Arch. Oral. Biol., vol. 51(9), pp. 784-93. 2006.
[13] Y. Watanabe, et. al., "Pharmaceutical evaluation of hollow type suppositories. IV. Improvement of bioavailability of propranolol in rabbits after rectal administration," J. Pharmacobiodyn., vol. 9. pp. 526- 531, 1986.
[14] Y. Watanabe, and M. Matsumoto, "Pharmaceutical evaluation of hollow type suppository. I. Brilliant blue FCF release characteristics of oleagenous hollow type suppository," Journal of the Pharmaceutical Society of Japan, vol. 104(5), pp. 479-484, 1984.
[15] British Pharmacopoeia. London: The Stationary Office; 2001: p. 2015, A235R.
[16] M. Tanaka, E. Kuwahara, M. Takahashi et al., "Enhanced rectal absorption of amphotericin B lyophilized with glycyrrhizinate in rabbits," Biol. Pharm. Bull., vol. 21, pp.853-857, 1998.
[17] E.A. Hosny, S.S. Abdeel-Hady, and K. El-Tahir, "Formulation, in vitro release and ex vivo spasmolytic effects of mebeverine hydrochloride suppositories containing polycarbophil or polysorbate 80," Int. J. Pharm., vol. 142, pp.163-168, 1996.